291 related articles for article (PubMed ID: 20089807)
41. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
Girard D; Finegan SM; Dunne MW; Lame ME
J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
[TBL] [Abstract][Full Text] [Related]
42. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2007 May; 321(2):598-607. PubMed ID: 17283225
[TBL] [Abstract][Full Text] [Related]
44. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.
Sharma A; Davis CB; Tobia LA; Kwok DC; Tucci MG; Gore ER; Herzyk DJ; Hart TK
J Pharmacol Exp Ther; 2000 Apr; 293(1):33-41. PubMed ID: 10734150
[TBL] [Abstract][Full Text] [Related]
45. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
46. Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.
Parng C; Singh P; Pittman DD; Wright K; Leary B; Patel-Hett S; Rakhe S; Stejskal J; Peraza M; Dufield D; Murphy JE; Webster R
J Pharm Sci; 2018 Jul; 107(7):1995-2004. PubMed ID: 29571739
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.
Chow FS; Benincosa LJ; Sheth SB; Wilson D; Davis CB; Minthorn EA; Jusko WJ
Clin Pharmacol Ther; 2002 Apr; 71(4):235-45. PubMed ID: 11956506
[TBL] [Abstract][Full Text] [Related]
48. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody.
Glantschnig H; Scott K; Hampton R; Wei N; McCracken P; Nantermet P; Zhao JZ; Vitelli S; Huang L; Haytko P; Lu P; Fisher JE; Sandhu P; Cook J; Williams D; Strohl W; Flores O; Kimmel D; Wang F; An Z
J Pharmacol Exp Ther; 2011 Aug; 338(2):568-78. PubMed ID: 21531794
[TBL] [Abstract][Full Text] [Related]
49. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
50. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
[TBL] [Abstract][Full Text] [Related]
51. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
53. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
[TBL] [Abstract][Full Text] [Related]
54. A physiologically based pharmacokinetic model for fluoride uptake by bone.
Rao HV; Beliles RP; Whitford GM; Turner CH
Regul Toxicol Pharmacol; 1995 Aug; 22(1):30-42. PubMed ID: 7494900
[TBL] [Abstract][Full Text] [Related]
55. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
56. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
57. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
59. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?
Daoussis D; Andonopoulos AP
Semin Arthritis Rheum; 2011 Oct; 41(2):170-7. PubMed ID: 21435697
[TBL] [Abstract][Full Text] [Related]
60. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
